PT1165126E - Processo para a preparação de uma vacina para o papilomavírus humanos com partículas semelhantes a vírus desagregadas e reagregadas - Google Patents

Processo para a preparação de uma vacina para o papilomavírus humanos com partículas semelhantes a vírus desagregadas e reagregadas Download PDF

Info

Publication number
PT1165126E
PT1165126E PT00918248T PT00918248T PT1165126E PT 1165126 E PT1165126 E PT 1165126E PT 00918248 T PT00918248 T PT 00918248T PT 00918248 T PT00918248 T PT 00918248T PT 1165126 E PT1165126 E PT 1165126E
Authority
PT
Portugal
Prior art keywords
vlps
hpv
buffer
process according
nacl
Prior art date
Application number
PT00918248T
Other languages
English (en)
Portuguese (pt)
Inventor
David B Volkin
Henryk Mach
Li Shi
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1165126(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PT1165126E publication Critical patent/PT1165126E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT00918248T 1999-03-26 2000-03-22 Processo para a preparação de uma vacina para o papilomavírus humanos com partículas semelhantes a vírus desagregadas e reagregadas PT1165126E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles

Publications (1)

Publication Number Publication Date
PT1165126E true PT1165126E (pt) 2006-12-29

Family

ID=26824774

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00918248T PT1165126E (pt) 1999-03-26 2000-03-22 Processo para a preparação de uma vacina para o papilomavírus humanos com partículas semelhantes a vírus desagregadas e reagregadas

Country Status (19)

Country Link
US (2) US6245568B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1165126B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4594534B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20020013516A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR023166A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE339222T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU778937B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2368391C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (4) CY1105779T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (4) DE122007000033I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1165126T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2270822T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR07C0026I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1165126I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (3) LU91328I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (3) NL300268I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1165126E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1165126T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000057906A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
WO2001042780A1 (en) * 1999-12-09 2001-06-14 Medimmune, Inc. IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003213060A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003287980B2 (en) 2002-11-01 2009-06-25 Glaxosmithkline Biologicals S.A. Drying process
DE60336581D1 (de) 2002-12-20 2011-05-12 Glaxosmithkline Biolog Sa Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
EP1785433A4 (en) * 2004-07-01 2008-10-01 Tokyo Inst Tech VIRAL PARTICLE-LIKE CONSTRUCTION AND PROCESS FOR FORMING THE SAME IN PHYSIOLOGICAL CONDITIONS
PE20060958A1 (es) * 2005-01-25 2006-10-27 Wyeth Res Ireland Ltd Protectores contra el esfuerzo cortante en la microfiltracion de la cosecha
WO2007011711A2 (en) * 2005-07-14 2007-01-25 Mayo Foundation For Medical Education And Research Paramyxoviridae virus preparations
US20090105130A1 (en) * 2005-08-12 2009-04-23 Astellas Pharma Inc. Depsipeptide-containing injection solution
CN101291689B (zh) * 2005-09-01 2012-12-05 若泽·路易斯·努诺·阿雅拉 用于大规模接种系统的活抗原的疫苗稳定化制剂
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN101460636A (zh) * 2006-05-11 2009-06-17 伯克顿迪金森公司 从细胞中提取蛋白质的方法
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
EP2258380B1 (en) * 2008-03-31 2013-03-13 Morinaga Milk Industry Co., Ltd. Nucleic acid for imparting heat resistance to lactoferrin
DK2473596T3 (en) 2009-09-03 2018-01-22 Becton Dickinson Co METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS
FI3831406T3 (fi) 2010-08-23 2024-08-06 Wyeth Llc Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP2015514696A (ja) 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
AU2014316722B2 (en) 2013-09-08 2017-09-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
WO2018152505A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Efficient cell free production of papillomavirus gene transfer vectors
KR102651043B1 (ko) 2017-10-30 2024-03-22 다케다 야쿠힌 고교 가부시키가이샤 지질-외피보유 바이러스의 불활성화를 위한 환경 친화적 세제
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE470434T1 (de) * 1997-02-06 2010-06-15 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
NZ500028A (en) 1997-04-08 2001-08-31 Merck & Co Inc Stabilized human papillomavirus formulations also containing a salt and a nonionic surfactant
EP1000157A1 (en) 1997-07-03 2000-05-17 University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy

Also Published As

Publication number Publication date
FR07C0026I2 (fr) 2012-08-03
DE60030698T2 (de) 2007-07-19
CY2007008I1 (el) 2009-11-04
CA2368391A1 (en) 2000-10-05
DE122007000032I1 (de) 2007-08-09
LU91328I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-03-01
LTPA2007002I1 (lt) 2020-03-25
CY2007010I1 (el) 2009-11-04
AU3909300A (en) 2000-10-16
LU91326I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-12-31
CA2368391C (en) 2011-06-07
JP4594534B2 (ja) 2010-12-08
NL300268I1 (nl) 2007-05-01
CY2007009I1 (el) 2010-07-28
EP1165126A1 (en) 2002-01-02
NL300270I1 (nl) 2007-05-01
ES2270822T3 (es) 2007-04-16
JP2002540167A (ja) 2002-11-26
CY2007010I2 (el) 2009-11-04
AR023166A1 (es) 2002-09-04
US20010021385A1 (en) 2001-09-13
DK1165126T3 (da) 2007-01-08
NL300269I1 (nl) 2007-05-01
DE122007000034I1 (de) 2007-08-09
FR07C0026I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2007-04-27
ATE339222T1 (de) 2006-10-15
DE60030698D1 (de) 2006-10-26
DE122007000033I1 (de) 2007-08-09
NL300269I2 (nl) 2008-07-01
AU778937B2 (en) 2004-12-23
LU91327I2 (fr) 2007-05-14
WO2000057906A1 (en) 2000-10-05
LU91327I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-03-01
CY2007009I2 (el) 2010-07-28
LU91328I2 (fr) 2007-05-14
CY1105779T1 (el) 2010-07-28
LTC1165126I2 (lt) 2020-04-27
SI1165126T1 (sl) 2006-12-31
LU91326I2 (fr) 2007-05-14
KR20020013516A (ko) 2002-02-20
EP1165126B1 (en) 2006-09-13
CY2007008I2 (el) 2009-11-04
US6245568B1 (en) 2001-06-12

Similar Documents

Publication Publication Date Title
PT1165126E (pt) Processo para a preparação de uma vacina para o papilomavírus humanos com partículas semelhantes a vírus desagregadas e reagregadas
EP1150712B1 (en) Human papilloma virus vaccine formulations
US12350375B2 (en) Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
RU2465007C2 (ru) Препарат вакцины на основе конъюгата никотин-носитель
JP4546092B2 (ja) ワクチン
PL212981B1 (pl) Kompozycja szczepionkowa, sposób jej wytwarzania, zastosowanie mieszaniny HPV 16, HPV 18, HPV 31 i HPV VLP oraz stabilizowana kompozycja szczepionkowa
EP2485766A1 (fr) Excipient stabilisant pour vaccin a virus entiers inactives
HUT70982A (en) Hepatitis a vaccine
US9827205B2 (en) Dry powder fibrin sealant
CN120475988A (zh) 免疫原性组合物及引发针对艰难梭菌的免疫应答的方法
RU2766292C1 (ru) Состав вакцины против covid-19
HK40064104A (en) Stabilising excipient for vaccine with inactivated whole viruses
JP2001526292A (ja) クエン酸またはトリエタノールアミンおよびそれらの組合せを含むｄｎａ医薬製剤
CN118900684A (zh) 制备佐剂的方法
EP0859846A1 (en) Rabies recombinant adenovirus
HK1167604B (en) Stabilising excipient for inactivated whole-virus vaccines